Physician profile
Ali Daoud
NPI 1265274930
$1,913.86
in general payments reported to CMS, 2019-2025
19 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $355 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.61 | 2025 | |
| Mallinckrodt Hospital Products INC. | $235.69 | 2025 | Terlivaz |
| Inari Medical, INC. | $221.79 | 2024-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Qol Medical, LLC | $126.00 | 2025 | Sucraid |
| Novo Nordisk INC | $124.99 | 2024 | |
| Gilead Sciences, INC. | $124.74 | 2025 | Epclusa |
| Janssen Biotech, INC. | $124.03 | 2025 | Tremfya |
| Amgen INC. | $121.84 | 2025 | |
| Boston Scientific Corporation | $120.00 | 2025 | Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $102.06 | 2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $94.50 | 2024 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.46 | 2025 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.93 | 2024-2025 | Lifevest |
| Averitas Pharma INC. | $47.31 | 2025 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.38 | 2024 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.24 | 2025 | |
| Lilly USA, LLC | $21.94 | 2025 | Mounjaro |
| Recor Medical INC | $17.35 | 2024 | Paradise Renal Denervation System |
| Dynavax Technologies Corporation | $9.00 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.